Initial Therapeutics is discovering and developing a new class of small-molecule medicines designed to halt pathogenic protein formation in the earliest stages.
Initial’s approach is unique and starkly differentiated from protein degradation and other interventions that recognize and tackle proteins only after they have been fully formed.
Company Details
- Employees
- 20
- Founded
- -
- Address
- 285 E Grand Ave, South San Francisco,california 94080,united States
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://initialtx.com/
- HQ
- South San Francisco, California
Initial Therapeutics Questions
Initial Therapeutics's website is https://initialtx.com/
Initial Therapeutics's LinkedIn profile is https://www.linkedin.com/company/initial-therapeutics
Initial Therapeutics has
20 employees.
View email and phone details for 20
employees at Initial Therapeutics.
Initial Therapeutics's industry is
Biotechnology Research
Initial Therapeutics's top competitors are
Bitterroot Bio,
Maze Therapeutics,
Rezo Therapeutics,
Evercrisp Biosciences,
Ascidian Therapeutics,
Deep Apple Therapeutics,
Juvena Therapeutics,
Atp (Apple Tree Partners),
Apertor Pharmaceuticals,
Nine Square Therapeutics.
Initial Therapeutics's categories are Biotechnology Research
Initial Therapeutics's founding year is 2020
